Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
HeartWare International said that it’s on track to restart a CE Mark trial for its MVAD implantable heart pump.
Investors initially pared 30.0% from HTWR shares after the company said Oct. 12 that it might not be able to resume the trial as soon as was expected. Framingham, Mass.-based HeartWare, which put a hold on enrollment in its CE Mark trial Sept. 9 due to controller manufacturing and software issues, added that it began investigating reports of adverse events in certain trial subjects “typical of those seen in other clinical trials for ventricular assist devices.” Read more
Smith & Nephew said that it agreed to acquire robot-assisted surgery company Blue Belt Technologies for $275 million, but missed top-line expectations for the 3rd quarter.
Minneapolis-based Blue Belt makes the portable Navio system, which is designed to work with 8 different knee systems, including Smith & Nephew’s Zuk and Journey Uni devices. The London-based medical products giant, noting that Blue Belt is its “most successful” implant sales partner, plans to continue to support implants from other manufacturers with the Blue Belt system. Read more
Baxter said that it tapped former Covidien chief José Almeida to replace Robert Parkinson Jr. as chairman & CEO after Parkinson’s retirement next year.
Almeida, who led Covidien to its $50 billion acquisition by Medtronic early this year, will start immediately at Deerfield, Ill.-based Baxter to get up to speed, the company said. Read more